Mesoblast -cell therapy products are referred to as American origin and not subject to rates

Mesoblast Limited (Nasdaq: Meso; ASX: MSB), world leader in allogeneous cellular medicines for inflammatory diseases, it today repeated that the allogeneous cell therapy products are made of US donors and referred to as American originated products.

Ryoncil ^® (Remestem cell L) is the only allogeneous mesenchymal stromal cell therapy approved By US Food and Drug Administration (FDA) for every indication. As documented in the Biological License Application (BLA) of the company, Ryoncil ^® is referred to as a ‘US Country of Origin’ product in accordance with the American FDA and Customs -statutory guidelines.

Ryoncil ^® has been approved for the treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractary acute transplant versus host disease (SR-AGVHD), a disorder with high mortality rates.

Mesoblast continues to ensure that all its products, either for SR-AGVHD, chronic heart failure, chronic back pain or other inflammatory indications, are manufactured from American donors in American locations.

About Mesoblast
Mesoblast (the company) is a world leader in the development of allogeneous (ready-made) cellular drugs for the treatment of severe and life-threatening inflammatory disorders. The therapies of the patented mesenchymal lineage cell therapy platform of the company respond to severe inflammation by releasing and modulating multiple effector arms of the immune system, resulting in a significant reduction of the harmful inflammatory process.

Mesoblast’s Ryoncil ^® (Remestemcel-L-RKND) for the treatment of steroid-reefractary acute transplant versus hostile disease (sr-agvHD) in pediatric patients 2 months and older is the first mesenchymal stromal cell (MSC) therapy approved by the FDA. See the full prescribing information www.nyoncil.com .

Mesoblast strives to develop extra cell therapies for various indications based on its remestem cell-L and Rexlemestrcel-L Allogeneous Stromal Celt technology platforms. Ryoncil ^® is being developed for extra inflammatory diseases, including SR-AGVHD in adults and biological resistant inflammatory bowel disorders. Rexlemestrcel-L is developed for heart failure and chronic low back pain. The company has set up commercial partnerships in Japan, Europe and China.

About Mesoblast Intellectual Property: Mesoblast has a strong and extensive global portfolio for intellectual property, with more than 1,000 patents or patent requests for mesenchymal stromal cell compositions of matter, production methods and indications. These patents and patent applications are expected to offer commercial protection that extends to at least 2041 in large markets.

About mesoblast production: The company’s own production processes yield industrial scale, cryopreservated, ready-made, cellular medicines. These cell therapies, with defined pharmaceutical gap criteria, are planned to be immediately available for patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, see www.mesoblast.com LinkedIn: Mesoblast Limited and Twitter: @menoblast

Foresighting statements
Dit persbericht omvat toekomstgerichte verklaringen die betrekking hebben op toekomstige gebeurtenissen of onze toekomstige financiële prestaties en bekende en onbekende risico’s, onzekerheden en andere factoren die onze werkelijke resultaten, activiteiten, prestaties of prestaties kunnen verschillen, materieel verschillen van toekomstige resultaten, niveaus van activiteit, prestaties, prestaties, prestaties, prestaties, prestaties, prestaties of prestaties, prestaties, prestaties of prestaties, prestaties, prestaties of prestaties, prestaties, prestaties of prestaties, Performance, performance or performance, performance, performance or performance, performance or performance, expressed or implied by these foresighting explanations. We make such future-oriented statements based on the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward -looking statements should not be read as a guarantee for future performance or results, and the actual results may differ from the results expected in these future -oriented statements, and the differences can be equipment and adverse. Force-seeing statements include, but are not limited to statements about: the initiation, timing, progress and results of the pre-clinical and clinical studies of Mesoblast, and the research and development programs of Mesoblast; Mesoblast’s ability to promote product candidates in, to register and to complete it successfully, clinical studies, including multinational clinical studies; The ability of Mesoblast to promote the production possibilities; the timing or probability of legal archives and approvals, production activities and product marketing activities, if applicable; The commercialization of the Mesoblast Ryoncil ^® for Pediatric SR-AGVHD and all other product candidates, if approved; legal or public perceptions and market acceptance on the use of Stam-Cel-based therapies; the potential for the product candidates of Mesoblast, if present, must be approved to be withdrawn from the market due to the patient’s side effects or deaths; the potential benefits of strategic cooperation agreements and the ability of Mesoblast to enter into and maintain established strategic collaborations; Mesoblast’s capacity to set up and maintain intellectual property on his product candidates and Mesoblast’s assets to successfully defend them in cases of alleged infringement; The scope of Mesoblast protection is able to determine intellectual property rights and to maintain its product candidates and technology; estimates of the costs of Mesoblast, future income, capital requirements and its needs for additional financing; Mesoblast’s financial performance; Developments with regard to competitors and the industry of Mesoblast; And the prices and reimbursement of the product candidates from Mesoblast, if approved. You must read this press release together with our risk factors, in our most recently submitted reports with the SEC or on our website. Uncertainties and risks that can lead to the actual results, performance or performance of Mesoblast differ material from those that can be expressed or implied by such statements, and accordingly you should not place unnecessary dependence on these future -oriented statements. We make no obligations to publicly update or revise public statements, either as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.